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ABSTRACT
PRMT1, an arginine methyltransferase, plays an
important role in numerous cellular processes. In
this study, we demonstrate a feedback regulatory
loop between PRMT1 and the orphan receptor
TR3. Unlike another orphan receptor HNF4, TR3 is
not methylated by PRMT1 although they physically
interact with each other. By delaying the TR3 protein
degradation, PRMT1 binding leads to the elevation
of TR3 cellular protein level, thereby enhances the
DNA binding and transactivation activity of TR3 in a
non-methyltransferase manner. Another coactivator
SRC-2 acts synergistically with PRMT1 to regulate
TR3 functions. In turn, TR3 binding to the catalytic
domain of PRMT1 causes an inhibition of the PRMT1
methyltransferase activity. This repression results
in the functional changes in some of PRMT1 sub-
strates, including STAT3 and Sam68. The negative
regulation of PRMT1 by TR3 was further confirmed
in both TR3-knockdown cells and TR3-knockout
mice with the use of an agonist for TR3. Taken
together, our study not only identifies a regulatory
role of PRMT1, independent on methyltransferase
activity, in TR3 transactivation, but also charac-
terizes a novel function of TR3 in the repression of
PRMT1 methyltransferase activity.
INTRODUCTION
Arginine methylation, a common post-translational mod-
iﬁcation mainly occurring in nuclear proteins of eukaryo-
tic cells, is catalyzed by a family of enzymes named protein
arginine methyltransfeases (PRMTs) (1). In humans,
PRMTs represent a family of 11 known enzymes that
utilize S-adenosyl methionine (AdoMet) as a methyl
donor (2). The substrates of these PRMTs include glycine
arginine-rich (GAR) nucleic acid-binding proteins (3).
PRMT1, the ﬁrst identiﬁed arginine methyltransferase, is
known to distribute throughout the cell and preferentially
binds to GAR motifs within its substrates (4,5). PRMT1
shows a wide spectrum of substrates and is responsible
for most of the arginine methylation reaction. RNA-
binding proteins, histones and the DNA damage response
proteins are known to be PRMT1 substrates (6). PRMT1
methylation has been shown to regulate a variety of cel-
lular processes including transcription, RNA metabolism,
translocation, signaling transduction, DNA repair and
apoptosis.
Although mice with PRMT1
–/– knocked out die shortly
after implantation, embryonic stem cells from such
embryos are viable under cell culture conditions (7), indi-
cating that PRMT1 is an essential enzyme but dispensable
for basic cellular reaction such as gene expression and
DNA replication. The major targets of PRMT1 are
nuclear proteins such as the orphan receptor HNF4
(8–10). PRMT1 modulates HNF4 transcriptional activity
in two ways. On the one hand, it regulates the DNA-
binding activity of HNF4; on the other hand, it methylates
histones and acts synergistically with other coactivators at
the promoters of HNF4 targets (11). PRMT1 methylation
on nucleosomal histones also plays an important and
dynamic role in nuclear receptor-mediated transcriptional
regulation, chromation remodeling and other aspects of
gene expression (12,13).
The enzymatic activity of PRMTs can be modulated by
multiple manners, such as regulation of their expression,
formation of macromolecules, changing accessibility of
the enzyme to the substrate, other post-translational mod-
iﬁcations and protein–protein interactions. For example,
BTG1 and TIS21/BTG2 bind PRMT1 and stimulate its
activity toward selected substrates (4). Binding of the
tumor suppressor DAL-1 to PRMT3 acts as an inhibitor
of its enzymatic activity, both in in vivo reaction and inside
the cells (14,15). Protein phosphatase 2A (PP2A) inhibits
PRMT1 activity and therefore not only increases the
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is inhibited by methylation) but also represses interferon-
induced signaling through STAT1 to strengthen the cellu-
lar defense against viruses (16). It is proposed that some
additional yet-to-be-identiﬁed factor(s) may multimerize
PRMTs in vivo to regulate their activities (17).
Nuclear orphan receptor TR3 (also termed as ‘Nur77’
and ‘NGFI-B’) is a transcription factor that plays key
roles in cell proliferation and apoptosis at both transcrip-
tional and post-transcriptional levels (18). More recently,
we have found that p300-induced p53 acetylation can be
dramatically suppressed by TR3at the transcriptional
level (19). By blocking the acetylation, TR3 downregulates
p53 transcriptional activity and leads to a decrease in the
transcription level of MDM2 (19). Similarly, TR3 also
signiﬁcantly inhibits the p300-induced RXRa acetylation,
resulting in the disassociation of RXRa from DNA,
and the translocation of TR3/RXRa from the nucleus to
mitochondria to induce apoptosis upon 9-cis retinoic acid
stimulation (20). Further analysis revealed that TR3 nega-
tively regulates the acetylation and transcriptional activity
of many p300-regulated transcription factors through
physical interaction (21).
In this study we investigated whether TR3 is subjected
to PRMT1 methylation just like the other orphan receptor
HNF4. Our results indicated that TR3 is not a substrate of
PRMT1. However, PRMT1 could interact with TR3 and
resulted in elevation of its cellular protein level, thus pro-
moted the DNA binding and transactivation activity of
TR3. On the other hand, we unexpectedly found that
accumulated TR3 in turn inhibited PRMT1 methyltrans-
ferase activity by masking its catalytic domain. We further
conﬁrmed the inhibitory eﬀect of TR3 on PRMT1 methyl-
transferase activity in both TR3-knockdown cells and
TR3-knockout (KO) mice with the use of an agonist for
TR3. Together, our study uncovers a novel molecular
mechanism by which PRMT1 and TR3 form a feedback
regulatory loop to modulate their functions mutually.
MATERIALS AND METHODS
Cell cultureand transfection
Human embryonic kidney cells HEK293T (obtained from
the ATCC, USA) and human hepatocellular liver carci-
noma cells HepG2 (purchased from Cell Biology Institute,
Shang-Hai, China) were grown in Dulbecco’s modiﬁed
Eagle’s medium (DMEM) supplemented with 10% fetal
calf serum, 100U/ml penicillin and 100mg/ml streptomy-
cin in a humidiﬁed atmosphere of 5% CO2at 378C.
Transfection was performed using calcium phosphate pre-
cipitation method as described previously (19).
Preparation of cytosolic and nuclearfractions
Harvested cells were suspended in 100ml Buﬀer A (10mM
HEPES, pH 7.9, 10mM KCl, 0.1mM EDTA, 0.1mM
EGTA, 0.15% NP-40) containing 1% protease inhibitor,
followed by a 15-min incubation. Homogenates were
centrifuged at 12000g for 1min at 48C, and the super-
natant (cytosolic fraction) was stored at –808C. The
pellet was washed with 1ml Buﬀer A, then resuspended
in 150ml Buﬀer B (20mM HEPES, pH 7.9, 0.4mM NaCl,
1mM EDTA, 1mM EGTA, 0.5% NP-40) containing 1%
protease inhibitor and sonicated at 48C. Cellular debris
was removed by centrifugation at 12 000g for 30min
at 48C and the supernatant (nuclear fraction) was stored
at –808C.
Immunoprecipitation and westernblotting (Co-IP assay)
Cells were transfected with various plasmids as required
and harvested at 36h post-transfection. Cell lysate pre-
paration, immunoprecipitation and western blotting
were performed as described previously (21). Brieﬂy, cell
lysates were incubated with the appropriate antibody for
2h, and subsequently incubated with protein A-Sepharose
beads for 1h. The protein–antibody complexes that were
recovered on beads were subjected to western blot analysis
using diﬀerent antibodies as required after separation
by SDS-PAGE. The immunoreactive products were
then detected by using Enhanced chemiluminescence kit
(Amersham).
Eletrophoretic mobility shift assay(EMSA)
For the in vitro EMSA, GST fusion proteins of PRMT1,
TR3 and its deletion mutants as indicated were expressed
in BL21 cells, and EMSA was performed as described
previously (20,22) with biotin-labeled NurRE oligo-
nucleotide (50-GATCCGTGACCTTTATTCTCAAAGG
TCA-30; Invitrogen, Shanghai, China) (23).
For the in vivo EMSA, cells were transfected with dif-
ferent expression vectors as required, and nuclear extracts
were prepared as described previously (24). EMSA was
performed as described above.
Chromatin immunoprecipitation (ChIP) assay
Cells were cross-linked by adding formaldehyde directly to
culture medium to a ﬁnal concentration of 1% and incu-
bated for 10min at 378C. Pellets were suspended in 200ml
of SDS lysis buﬀer (1% SDS, 10mM EDTA and 50mM
Tris, pH 8.1), then sonicated. After centrifugation, 10% of
the total supernatant was saved as total input control.
The remaining supernatant was diluted by 10-fold in
ChIP dilution buﬀer (0.01% SDS, 1.1% Triton X-100,
1.2mM EDTA, 16.7mM Tris–HCl, pH 8.1, 167mM
NaCl), and then divided into two parts, incubating with
or without 2mg of anti-TR3 antibody (Santa Cruz) over-
night at 48C. After immunoprecipitation, 60ml of salmon
sperm DNA/Protein-A agarose was added, and incubated
for another 1h at 48C. Sepharose beads were washed
sequentially in low salt immune complex wash buﬀer
(0.1% SDS, 1% Triton X-100, 2mM EDTA, 20mM
Tris–HCl, pH 8.1, 150mM NaCl) once, high salt
immune complex wash buﬀer (0.1% SDS, 1% Triton
X-100, 2mM EDTA, 20mM Tris–HCl, pH 8.1, 500mM
NaCl) once, LiCl immune complex wash buﬀer (0.25M
LiCl, 1% IGEPAL CA630, 1% deoxycholic acid, 1mM
EDTA, 10mM Tris, pH 8.1) once, and 1 TE for two
times. Beads were then extracted with 500-ml elution
buﬀer (1% SDS, 0.1M NaHCO3). 20ml 5M NaCl and
2ml of RNase A (0.5mg/ml) were added and heated at
658C for 5h to reverse the formaldehyde cross-linking.
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were showed as below:
CyclinD2promoter:Sense:50 CCTCCCTCTTCTTCCT
CTGC30;antisense:50 TCCTAATCCTCCTGCCCTTG 30
GAPDH promoter: Sense: 50 GAGATGCCAGGAGC
CAGGAGATG 30; antisense: 5’ GAAACAGGAGGACT
TTGGGAACG 30
Invitro methylation assay
PRMT1, GAR, TR3 and its deletions were prepared as
recombinant glutathione S-transferase (GST) fusion pro-
tein and eluted from glutathione-agarose beads with
20mM glutathione. Myc-PRMT1, Myc-Sam68, and
Flag-STAT3 were expressed in 293T cells and immuno-
precipitated with anti-Myc (Roche) and anti-Flag (Sigma)
antibodies. Ten micrograms of substrate proteins were
respectively incubated with 1mg of GST-PRMT1 or
immunoprecipitated Myc-PRMT1 and 6mlo fS-adeno-
syl-L-[methyl-3H]methionine (Amersham) or 600mM nor-
adioactive S-adenosylmethionine (NEB) in 30mlo f
methyltransferase reaction buﬀer [20mM Tris–HCl (pH
8.0), 200mM NaCl, 0.4mM EDTA] at 308C for 2h.
Reactions were stopped by adding 30mlo f2  SDS-
PAGE sample buﬀer, followed by heating at 1008C for
10min. Samples were loaded on SDS-polyacrylamide
gels and analyzed by Coomassie blue staining and western
blotting. For ﬂuorography, gels were treated with
EN3HANCE (Perkin-Elmer Life Sciences) as per the
manufacturer’s instructions, dried and exposed at –808C
for 2 weeks.
Luciferase assay
Cells were transfected with pGL3-NurRE, pGL3-promo-
ter vector or APRE luciferase reporter genes, b-galactosi-
dase (b-gal) and other diﬀerent expression vectors as
required. After transfection, luciferase activity was nor-
malized for transfection eﬃciency using corresponding
b-gal activity. The ratios of luciferase/b-gal activity were
used as indicators for transcriptional activity of diﬀerent
promoters.
GST pull-down assay
GST pull-down assay was performed as described pre-
viously (19). Approximately 1mg of GST or GST-TR3
immobilized to 10ml of glutathione-Sepharose 4B was
incubated with 0.5–1.0mg of His-PRMT1 in 500mlo f
modiﬁed GBT buﬀer (10% glycerol, 50mM HEPES-
NaOH (pH 8.0), 170mM KCl, 7.5mM MgCl2, 0.1mM
EDTA, 1mM DTT, 1% Triton X-100) containing 1%
bovine serum albumin. After extensively washing with
GBT buﬀer, the bound proteins were fractionated by
10% SDS-PAGE and subjected to Coomassie brilliant
blue staining and western blot.
Invivo ubiquitination assay
Cells were transfected with expression vectors as required.
After transfection, 20% of cells were used for western blot
analysis; the other cells were lysed in Buﬀer A (6M gua-
nidine HCl, 0.1M Na2HPO4/NaH2PO4, 0.01M Tris/HCl,
pH 8.0, 10mM b-mercaptoethanol, 5mM imidazole,
0.2% Triton X-100 and fresh protease inhibitors).
Lysates were mildly sonicated to reduce viscosity, and
ubiquitinated proteins were bound for 4h at room tem-
perature in 50ml of nickel-nitrilotriacetic acid-agarose
(Ni–NTA-agarose; QIAGEN, Valencia, CA). The beads
were successively washed once for 5min at room tempera-
ture with 1ml of each of Buﬀer A, Buﬀer B (8M urea,
0.1M Na2HPO4/NaH2PO4, 0.01M Tris/HCl, pH 8.0,
10mM b-mercaptoethanol, 5mM imidazole), Buﬀer C
(8M urea, 0.1M Na2HPO4/NaH2PO4, 0.01M Tris/HCl,
pH 6.3, 10mM b-mercaptoethanol, 5mM imidazole). The
bound proteins were fractionated by 10% SDS-PAGE
and subjected to western blotting.
5-Bromo-2-deoxyuridine (BrdU)incorporation assay
Cells were transfected with expression vectors as required
and incubated with BrdU (20mM; Sigma) for 2h. After
washing with PBS, harvested cells were ﬁxed with 4%
paraformaldehyde for 30min at room temperature and
then incubated with PBS containing 0.1% saponin
(Sigma) for another 10min. The cells were resuspended
in the buﬀer (0.1M NaAc, pH=5.2, 5M MgSO4) contain-
ing 30mg DNase I and incubated for 30min. After block-
ing for 30min at 378C, the cells were incubated with anti-
BrdU antibody and then PE-linked anti-mouse antibody.
Finally, cells were analyzed by ﬂow cytometer (Beckman
Coulter).
Immunofluorescent staining and microscopic observation
Cells that seeded on cover glass overnight were ﬁxed in
4% paraformaldehyde. To stain exogenous sam68, cells
were incubated with anti-Myc antibody, followed by
Texas red-conjugated secondary antibody. Nucleus was
stained by DAPI (Roche). Stained cells were visualized
with confocal microscope (Leica TCS SP2 SE).
RESULTS
PRMT1 binds toTR3 and elevates its cellular protein level
Although the arginine methyltransferase PRMT1 displays
a broad spectrum of substrate speciﬁcity (6), most of
its substrates contain glycine- and arginine-rich (GAR)
sequences including multiple arginines in RGG or RXR
contexts (3,25,26). Similar to 53BP1 and hnRNP K, two
known methylation substrates of PRMT1, TR3 also con-
tains a ‘GRRGR’ motif within its DNA-binding domain
(Figure 1A), suggesting that it might be a potential target
of PRMT1. To test this possibility, we constructed several
GST-fusion proteins, including full-length TR3, TR3
(DBD) (DBD, DNA-binding domain), TR3(TAD+
DBD) (TAD, transactivation domain) and TR3(LBD)
(LBD, ligand-binding domain) (Figure 1A). When these
proteins were incubated with PRMT1 that was immuno-
precipitated from transfected cells, we could not detect
any methylation signal (Figure 1B). On the other hand,
the methylation of GST-GAR (GST fusion protein con-
taining the glycine- and arginine-rich N-terminal region of
ﬁbrillarin) by PRMT1 was clearly observed in the control
834 Nucleic Acids Research, 2009, Vol. 37, No. 3Figure 1. Upregulation of TR3 expression by PRMT1 is irrelevant to PRMT1 methylation activity. (A) Schematic presentation of the functional
domains of TR3 (Bottom) with the comparison of its potential methylation site with those in hnRNP K and 53BP1 (Top). (B) In vitro PRMT1
methylation assay. GST-TR3 and its truncation mutants were separately incubated with PRMT1 protein immunoprecipitated from 293T cells. GAR
was used as a positive control. (C) Eﬀect of PRMT1 and its point mutant PRMT1 (XGX) on TR3 expression. Increased Myc-PRMT1 or Myc-
PRMT1 (XGX) was transfected into 293T cells with or without Myc-TR3. The expression level of TR3 was assayed by western blotting with anti-
myc or -TR3 antibody. Tubulin was used as the loading control. (D) Eﬀect of PRMT1 and its point mutant on TR3 stability. Flag-TR3 with or
without PRMT1/PRMT1(XGX) was transfected into 293T cells. The transfected cells were then treated with CHX (100mg/ml) for the indicated
times. TR3 expression levels were showed by western blotting using anti-Flag antibody (upper panel), and quantiﬁed by densitometry (down panel).
Error bars indicate standard deviations (SD) of three independent experiments. (E) PRMT1 attenuated the ubiquitination of TR3. 293T cells were
transiently transfected with Flag-TR3, His-ubiquitin or Myc-PRMT1 and subjected to the in vivo ubiquitination assay.
Nucleic Acids Research,2009, Vol. 37,No. 3 835experiment (Figure 1B). Together, these results suggest
that TR3 is not a methylation substrate of PRMT1 as
we previously thought.
Unexpectedly, we found that PRMT1 could dramati-
cally increase the cellular level of exogenous TR3 protein
in cotransfected 293T cells (Figure 1C, left panel). Such
eﬀect seemed not dependent on the TR3 expression vector,
as PRMT1 also elevated the endogenous level of TR3
protein in a dose-dependent manner (Figure 1C, right
panel). In addition, we noted that the ability of PRMT1
to upregulate TR3 protein level was not correlated with its
methyltransferase activity. When PRMT1(XGX), a point
mutant deﬁcient in methyltransferase activity (27), was
cotransfected into cells with TR3, it could still enhance
the cellular level of TR3 as eﬀectively as the wild-type
PRMT1 (Figure 1C). Therefore, the presence of PRMT1
protein, regardless of its methyltransferase activity,
imposes a positive regulation on the cellular level of
TR3 protein. In contrast, another arginine methyltransfer-
ase CARM1 had no eﬀect on the protein level of TR3
(Supplementary Figure A), indicating a speciﬁc role of
PRMT1 on regulation of TR3 level.
The increased TR3 level seen in PRMT1 transfected
cells could be a result of delayed protein degradation.
To verify this, we treated 293T cells with cycloheximide
(CHX), a protein synthesis inhibitor, to block the de novo
TR3 synthesis and monitored its lifetime at diﬀerent time
points by western blotting. As shown in Figure 1D,
the half-life time (the time required for a protein to be
degraded to 50%) of TR3 was slightly <12h in 293T
cells that transfected with TR3. With the coexpression of
PRMT1 or PRMT1(XGX), the half-life time of TR3 pro-
tein was signiﬁcantly prolonged to be >24h (Figure 1D).
It has been known that ubiquitin can target TR3 and
induces its degradation (22). However, addition of
PRMT1 abolished ubiquitin-induced TR3 degradation
(Figure 1E). Therefore, the presence of PRMT1 could
delay the degradation process of TR3 protein through
ubiquitination pathway. As a result, the total cellular
level of TR3 was elevated.
Based on the above results, we speculated that PRMT1
may physically interact with TR3. Therefore, 293T cells
were cotransfected with Flag-TR3 and Myc-PRMT1, and
subjected to Co-immunoprecipitation (Co-IP) assay.
As we expected, Flag-TR3 could readily be detected
by anti-Flag antibody once Myc-tagged PRMT1 or
PRMT1(XGX) was immunoprecipitated by the anti-Myc
antibody (Figure 1F). The physical interaction between
PRMT1 and TR3 was further conﬁrmed in vivo
by Co-IP assay, where TR3 was detected in PRMT1-
precipitated lysates (Figure 1G), and also in vitro
by GST pull-down assay, in which a strong and speciﬁc
Figure 1. Continued.
(F) PRMT1 interacts with TR3. Flag-TR3, with or without Myc-PRMT1 or PRMT1(XGX) was transfected into 293T cells. Cell lysates were
immunoprecipitated with anti-Myc antibody. The immunoprecipitates were then analyzed by western blotting using anti-Flag antibody for TR3
protein. (G) TR3 binds to PRMT1 in vivo. Cell lysates from 293T cells were immunoprecipitated with anti-PRMT1 antibody. The immunopreci-
pitates were then analyzed by western blotting using anti-TR3 antibody. (H) GST pull-down assay for determination of PRMT1-TR3 interaction
in vitro. GST-TR3 was incubated with His-PRMT1 protein, and then subjected to Coomassie brilliant blue staining and western blotting with anti-
His antibody to show TR3 and PRMT1 protein, respectively.
836 Nucleic Acids Research, 2009, Vol. 37, No. 3Figure 2. PRMT1 promotes the DNA binding and transactivation of TR3. (A) Determination of PRMT1-binding sites in TR3. Schematic diagrams
depict diﬀerent TR3 deletion mutants used in the domain mapping experiments (Top). 293T cells were transfected with Myc-PRMT1 and diﬀerent
Flag-TR3 deletion constructs as indicated. Cell lysates were immunoprecipitated with anti-Myc antibody. The immunoprecipitates were analyzed by
western blotting using anti-Flag antibody for TR3 proteins. (B, C) Eﬀect of PRMT1 on TR3 DNA binding. GST-TR3 and its deletion mutants,
including TAD+DBD and DBD+LBD, were incubated with GST-PRMT1 or its point mutant PRMT1(XGX), respectively, and then subjected to
the EMSA assay with the NurRE (for TR3 dimer binding) or NBRE (for TR3 monomer binding) as a probe. Speciﬁcity of the complexes was
assessed by competition with 200-fold excess of homologous unlabeled oligonucleotides or with anti-GST antibody to show the supershifted band.
(D) Eﬀect of PRMT1 on the transactivation of TR3. Increasing amount of PRMT1 and its mutant PRMT1(XGX), together with or without TR3
were transfected into 293T cells. NurRE-luciferase reporter gene and b-gal gene expression vector were transfected simultaneously. Reporter gene
activity was determined and normalized in relation to the cotransfected b-gal activity. Error bars indicate standard deviations (SD) of three
independent experiments. (E) Eﬀect of PRMT1 on the expression levels of E2F1 and Cyclin D2. Myc-PRMT1 or si-PRMT1 was transfected into
293T cells. The expression levels of PRMT1, TR3 and TR3-dependent downstream factors Cyclin D2 and E2F1 were assayed by western blotting
with anti-PRMT1, -TR3, -Cyclin D2 or –E2F1 antibodies. (F) PRMT1 regulates cell proliferation through TR3. Diﬀerent expression plasmids,
including Myc-PRMT1 and si-TR3, were transfected into 293T cells as indicated. The cells were then subjected to FACS as described in ‘Materials
and methods’ Section. TR3 and PRMT1 expression levels were showed by western blotting using anti-TR3 and anti-Myc antibodies (inset).
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(Figure 1H). Clearly, PRMT1 can directly interact with
TR3 in vivo and in vitro.
PRMT1enhances the DNA-binding ability of TR3
We went on to dissect the domain of TR3 that interacts
with PRMT1 with the use of various TR3 truncation
mutants (Figure 2A, top). Co-IP assays revealed that dele-
tion of the C-terminus from TR3 (TR3/D2) abolished its
binding to PRMT1 (Figure 2A, bottom), indicating that
the C-terminus is a crucial region for TR3-PRMT1 inter-
action. Further mapping analysis demonstrated that LBD
(aa 440–598) is the predominant PRMT1-binding region,
although the DBD also showed a very weak interaction
with PRMT1 (Figure 2A, bottom).
Next, we carried out EMSA assay to assess whether
PRMT1 enhances TR3 binding to its cognate element by
using the TR3 response element (NurRE) as a probe (22).
As shown in Figure 2B, GST-TR3 could bind to the
NurRE, forming a dimeric complex, and this complex
was completely dissociated by the addition of a competitor
or showed a supershift band by incubation with GST
antibody. When GST-TR3 was preincubated with
GST-PRMT1, its binding to DNA was enhanced and
became stronger when the amount of PRMT1 was
increased (Figure 2B, left). Similar results were observed
when PRMT1(XGX) mutant protein was used (Figure 2B,
right), indicating that PRMT1 methyltransferase activity
is not involved in the regulation of TR3 DNA binding. As
a negative control, the complex of TR3 was not inﬂuenced
by incubation with GST (Supplementary Figure B). We
further used TR3 truncation mutants to perform the par-
allel experiments. Due to the existence of the DBD, both
TR3(TAD+DBD) and TR3(DBD+LBD) all bound to
the NurRE, respectively (Figure 2C). However, only the
NurRE-binding activity of TR3(DBD+LBD), but not
TR3(TAD+DBD), could be enhanced upon incubation
with PRMT1 (Figure 2C). Since PRMT1 mainly interacts
with LBD but not TAD or DBD (Figure 2A), this result
strongly suggests that the interaction of PRMT1 with TR3
plays a positive regulatory role in TR3 DNA-binding
activity.
It is expected that the enhanced DNA-binding activity
of TR3 by PRMT1 would consequently aﬀect the trans-
activation of TR3, we therefore measured TR3 transacti-
vation in transient transfection cells by luciferase assay,
in which a construct containing two TR3 homodimer-
binding sites (NurRE) linked to luciferase reporter gene
(pGL3-promoter) (19) was used. As shown in Figure 2D,
PRMT1 and PRMT1(XGX) could activate the transcrip-
tional activity of reporter gene in a dose-dependent
manner, in the presence of endogenous or exogenous
TR3, which showed a good consistency with the eﬀect of
PRMT1 on TR3 DNA binding. As a negative control,
PRMT1 and PRMT1(XGX) did not showed any eﬀect
on the activation of pGL3-promoter vector, a nonrelated
reporter gene (Supplementary Figure C), suggesting a
selective activation of PRMT1 for TR3 transactivation.
Since PRMT1 enhanced the transactivation of TR3, it is
of interest to determine whether PRMT1 inﬂuences the
expression levels of TR3 downstream factors, such as
E2F1 and Cyclin D2 (28,29). Consistent with our specula-
tion, the expression levels of both E2F1 and Cyclin
D2 were upregulated by overexpression of PRMT1, but
downregulated by knockdown of endogenous PRMT1
(Figure 2E). Since both E2F1 and Cyclin D2 play
Figure 2. Continued.
838 Nucleic Acids Research, 2009, Vol. 37, No. 3important role in cell proliferation, we ﬁnally evaluate the
biological relevant of the upregulation of TR3 transacti-
vation by PRMT1 with the method of BrdU incorpora-
tion assay. As shown in Figure 2F, PRMT1 transfected
293T cells exhibited much stronger BrdU incorporation
compared with the control, and the eﬀect of PRMT1
was impaired by the transfection of si-TR3. This result
suggests that PRMT1 stimulats the proliferation of 293T
cells through enhancing the activity of TR3.
SRC-2acts synergistically withPRMT1to regulate TR3
PRMT1 generally functions together with its coactivator
to achieve synergistic enhancement of nuclear receptor
function. Since steroid receptor coactivators (SRCs)
have been shown to be involved in TR3 transactivation
(42), we tested whether SRCs and PRMT1 could act
synergistically to regulate TR3. As shown in Figure 3A,
all three SRC members (SRC-1, -2 and -3) had very little
Figure 3. SRC-2 exerts a synergistic eﬀect with PRMT1 on TR3 transactivation. (A) Eﬀect of SRCs on TR3 transactivation. Increasing amount
of SRCs, including SRC-1, SRC-2 and SRC-3, with or without PRMT1 were transfected into 293T cells. The reporter gene activity of NurRE was
determined. (B) PRMT1 and SRC-2 enhanced the binding of TR3 to Cyclin D2 promoter. Myc-PRMT1, Myc-PRMT1 (XGX) and HA-SRC-2 were
transfected into 293T cells as indicated. The binding of TR3 to Cyclin D2 promoter was determined by ChIP assay using anti-TR3 antibodies, and
then quantiﬁed by qPCR. (C) Eﬀect of PRMT1/SRC-2 on endogenous TR3 binding to the NurRE. Myc-PRMT1 and HA-SRC-2 were transfected
into 293T cells as indicated. Nuclear extracts were prepared, with or without incubated with anti-TR3 antibody, and then subjected to the EMSA
assay with the NurRE or NBRE as a probe. (D) Both PRMT1 and SRC-2 bound to TR3. 293T cells were transfected with Flag-TR3, HA-PRMT1
and HA-SRC-2. Cell lysates were immunoprecipitated with anti-HA antibody. The immunoprecipitates were then analyzed by western blotting using
anti-Flag antibody to show the interaction of TR3 with PRMT1 and SRC-2, respectively. (E) SRC-2 interacted with TR3 in vivo. 293T cells were
lysated and immunoprecipitated with anti-TR3 antibodies. The pellets were subjected to western blotting using anti-SRC-2 antibody. IgG was set as
a negative control. (F) SRC-2 but not PRMT1 enhanced TR3-PRMT1 interaction. 293T cells were transfected with diﬀerent plasmids as indicated.
After transfection, cells lysates were immuoprecipitated with anti-Myc or anti-Flag antibodies, and then the immunoprecipitates were subjected to
western blotting. (G) Determination of SRC-2-binding sites in TR3. 293T cells were transfected with HA-SRC-2 and diﬀerent Flag-TR3 deletion
constructs as indicated in Figure 2A. Cell lysates were immunoprecipitated with anti-HA antibody. The immunoprecipitates were analyzed by
western blotting using anti-Flag antibody for TR3 proteins. (H) Synergistic eﬀect of SRC-2 with PRMT1 on TR3 transactivation. 293T cells
were transfected with increasing amount of PRMT1, together with GAL4 reporter gene and GAL4-TAD or GAL4-LBD in the absence or presence
of SRC-2 as indicated. The luciferase activity was then determined.
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in the absence of PRMT1. However, with the co-presence
of PRMT1 and SRC-2 but not SRC-1 or SRC-3 displayed
a strong synergistic eﬀect to stimulate TR3 transactiva-
tion (black bars). As a negative control, SRC-2 did
not inﬂuence the transactivation of pGL3-promoter
vector, no matter whether PRMT1 was present or not
(Supplementary Figure D).
To further determine the synergistic role of SRC-2, we
carried out qChIP assay (quantitative chromatin immuno-
precipitation) with the use of cyclin D2 promoter that
contains a TR3 response element (29). Although either
SRC-2 or PRMT1 could help TR3 targeting to the
cyclin D2 promoter, this binding was enhanced when
both coactivators were used together (Figure 3B, lane 4
versus lane 2 or lane 3). Similar result was also observed
when SRC-2 and PRMT1(XGX) were used (lane 6 versus
lane 5). However, as a negative control, PRMT1 and
SRC-2 showed no eﬀect on nonrelated gene GAPDH
(Supplementary Figure E). Moreover, in the in vivo
EMSA assay, the complex formed in nuclear extracts
was TR3 protein, as this complex was supershifted when
nuclear extracts were incubated with anti-TR3 antibody
(Figure 3C). Similarly, the amount of TR3-bound NurRE
increased following the presence of PRMT1 or SRC-2,
and reached a maximum when both were presented.
This result further conﬁrmed that SRC-2 exerts a syner-
gistic eﬀect with PRMT1 to activate TR3 transactivation
through promoting TR3 DNA binding.
The above results suggest that SRC-2 may also bind
to TR3 in a similar way as PRMT1. We thus conducted
a Co-IP assay to test this possibility. Indeed, when HA-
tagged SRC-2 or PRMT1 was immunoprecipetated, the
Flag-TR3 could be detected (Figure 3D). As reported by
other group that TR3 and SRC-2 bound to each other
in vitro (30), we also conﬁrmed the interaction between
TR3 and SRC-2 in vivo (Figure 3E). To further evaluate
the mutual inﬂuence on the binding with TR3, diﬀerent
amount of SRC-2 or PRMT1 were transfected into 293T
cells. As shown in Figure 3F, with the increasing expres-
sion of SRC-2, the interaction between PRMT1 and TR3
became much stronger. In contrast, PRMT1 could not
enhance the interaction between TR3 and SRC-2. Again,
this result supports SRC-2 synergistic eﬀect on TR3-
PRMT1 interaction. We went on to determine the
region of TR3 that interacts with SRC-2 by coexpressing
diﬀerent truncation mutants of TR3 in 293T cells. Co-IP
assays showed that TR3/D1 and TR3/D4, but not TR3/
D2 and TR3/D3, retained the ability to interact with
SRC-2 (Figure 3G). Compared with the result of
PRMT1 interaction with TR3, we conclude that PRMT1
and SRC-2 all bind to the LBD of TR3, with PRMT1
mainly targeting to aa 440–598 and SRC-2 mainly target-
ing to aa 377–440.
The fact that both PRMT1 and SRC-2 bind to the LBD
of TR3 suggests that the LBD might function as the major
TR3 transactivation domain in response to PRMT1 and
SRC-2. To test this possibility, the assay for luciferase
activity was performed. 293T cells were transfected with
a chimeric GAL4-TR3, GAL4-TR3(TAD) (containing the
AF-1 domain) or GAL4-TR3(LBD) (containing the AF-2
domain), together with a construct containing ﬁve GAL4
response elements linked to a luciferase reporter gene
(pGAL4). Consistent with the previous report that trans-
activation of AF-1 was more powerful than AF-2 (30),
cells transfected with TR3(TAD) showed a higher lucifer-
ase activity than those transfected with TR3(LBD) in
the absence of PRMT1/SRC-2 (Figure 3H, bar 1 versus
bar 9). Cotransfection of PRMT1 slightly increased their
transactivation activity (Figure 3H, gray bars). However,
cotransfection of both SRC-2 and PRMT1 led to a sig-
niﬁcant activation on TR3(LBD) but not TR3(TAD)
(Figure 3H, black bars). This ﬁnding thus conﬁrms a coor-
dinate eﬀect of PRMT1 and SRC-2 on TR3 transactiva-
tion, and demonstrates the role of LBD as their major
mediator. In addition, we noted that transcriptional activ-
ity of GAL4-TAD was still diﬀerent in the absence
or presence of SRC-2, although endogenous PRMT1
was inhibited by its siRNA (Supplementary Figure F).
Figure 3. Continued.
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cofactors might be involved in the activation of GAL4-
TAD, while in the presence of SRC-2, these cofactors
might bridge SRC-2 targeting to the TAD of TR3, so
that SRC-2 still activates the GAL4-TAD.
TR3 inhibitsPRMT1 methyltransferase activity
PRMT1 is the only known enzyme that mediates asym-
metric dimethylation of Arg3 on Histone H4 (H4 R3)
(31,32). We did observe the methylation of H4 R3 by
PRMT1 in vitro with AdoMet as the methyl donor
(Figure 4A). However, when diﬀerent PRMT1 truncation
mutants were assay in vitro, no methylation signals
could be detected, even with the PRMT15 mutant
that had intact catalytic domain and dimerization arm
(Figure 4A). These results indicate that an intact
PRMT1 is critical for its methylation activity.
On the other hand, we are thinking why PRMT1 cannot
methylate TR3, although TR3 contains a glycine- and
arginine-rich motif ‘GRRGR’ in its DBD; and why
PRMT1 activates TR3 transactivational activity in a
non-methyltransferase fashion? One of possibilities
might be that TR3 in turn has an ability to aﬀect
PRMT1 methyltransferase activity. To test this, TR3
was introduced into cells and the methylation of H4 R3
was examined. As shown in Figure 4B, although TR3 did
not alter the expression level of either endogenous or exo-
genous PRMT1, it eﬀectively inhibited the methylation
level of H4 R3 in a dose-dependent manner. However,
overexpression of TR3 could not aﬀect the methylation
level of H3 R17 induced by CARM1 speciﬁcally
(Supplementary Figure G), indicating a speciﬁc role of
TR3 on PRMT1-induced methylation. Furthermore,
when siRNA was introduced into cells to knock down
endogenous TR3 levels, the methylation level of H4 R3
was greatly increased (Figure 4C). Similarly, the PRMT1-
induced GAR methylation could also be suppressed by
TR3 in vitro (Figure 4D). These results ﬁrmly demon-
strated that TR3 has a unique characteristic to inhibit
PRMT1 methyltransferase activity.
PRMT1 contains two important domains, the catalytic
domain and the substrate-binding domain (12). Some
of PRMT1 substrates, such as Histone H4, STAT3
or Sam68, were found to bind the substrate-binding
domain of PRMT1 (Supplementary Figure H–J).
However, in the current case, we unexpectedly found
that TR3 interacted with all the catalytic domain-
containing mutants (PRMT12, 4 and 5), but not
those catalytic domain-absent mutants (PRMT11
and 3) (Figure 4E), suggesting the importance of
catalytic domain in their interaction. We further
analyzed the eﬀect of PRMT1 truncation mutants on
TR3 transactivation activity and expression level.
Although 2, 4 and 5 all interacted with TR3,
only 4 was found to upregulate both the transactivation
and expression level of TR3 (Figure 4F and G),
demonstrating a key role for the N-terminus of PRMT1
in the regulation of TR3 functions. Finally, the methyla-
tion activity of PRMT1 could only be suppressed by
the TR3 deletion mutants (D1 and D4) that possess the
ability to bind PRMT1 (Figure 4H). Taken together, our
data reveal that TR3 directly targets to the catalytic
domain of PRMT1 to inhibit its methyltransferase
activity.
Figure 4. TR3 inhibits PRMT1 methyltransferase activity. (A) Full-
length PRMT1 but not its truncation mutants methylate H4 R3
in vitro. GST-PRMT1 and its mutants (Top) were incubated with
Histone and AdoMet, respectively. The reaction mixtures were resolved
on SDS-PAGE, and visualized by anti-methyl-H4 R3 antibody. (B, C)
TR3 exerted an inhibitory eﬀect on the methylation of H4 R3 in vivo.
Myc-TR3 (B) or siRNA-TR3 (C) was transfected into 293T cells with
or without PRMT1. The in vivo methylation of H4 R3 was examined.
(D) Eﬀect of TR3 on the in vitro methylation of GAR by PRMT1. The
methylation of GAR in vitro was determined with anti-dimethyl-argi-
nine asymmetric antibody (ASYM24). (E) TR3 interacts with PRMT1
truncation mutants. Diﬀerent GST-PRMT1 mutants were separately
incubated with Flag-TR3 protein immunoprecipitated from 293T cells
to detect their interactions by GST pull-down assay. (F) Eﬀect of
PRMT1 mutants on TR3 transactivational activity. Diﬀerent PRMT1
truncation mutants were transfected into 293T cells. The luciferase
activity of NurRE reporter gene was determined. (G) Eﬀect of
PRMT1 mutants on TR3 expression levels. Diﬀerent PRMT1 trunca-
tion mutants together with Flag-TR3 were transfected into 293T cells.
The expression levels of TR3 were determined by western blotting. (H)
Eﬀect of TR3 mutants on PRMT1-mediated H4 R3 methylation.
Diﬀerent TR3 mutants as indicated were transfected into 293T cells.
The in vivo methylation of H4 R3 was examined.
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Next, we investigated whether TR3 could negatively reg-
ulate PRMT1-mediated arginine methylation on a broad
spectrum of substrates under physiological conditions. We
examined the PRMT1-induced asymmetric dimethylation
in total cell lysates by using speciﬁc anti-dimethyl-arginine
asymmetric antibody. We could observe multiple methyl-
ated protein bands upon the expression of PRMT1.
However, coexpression of TR3 led to a decrease in the
methylation level of these proteins in a dose-dependent
manner (Figure 5A). Therefore, TR3 indeed inhibits
PRMT1-induced methylation of numerous cellular
proteins.
It is expected that TR3 suppression on PRMT1-depen-
dent methylation would aﬀect the functions of PRMT1
substrates. We analyzed the eﬀect of TR3 on Sam68 and
STAT3, two proteins known to be methylated by PRMT1
(33,34). Both STAT3 and Sam68 displayed a PRMT1-
dependent methylation, which could be abolished by the
transfection of siRNA against PRMT1 in 293T cells
(Figure 5B and C). As we expected, TR3 exerted an atte-
nuated eﬀect on methylation of these two proteins as eﬀec-
tively as AdOx, a global methylation inhibitor (Figure 5B
and C). Conversely, this methylation was enhanced when
si-TR3 was introduced into the same cell line (Figure 5D
and E). We also noted that TR3 mutant (TR3/D2) which
did not interact with PRMT1 lost its ability to regulate
PRMT1-induced methylation of STAT3 and Sam68
(Figure 5D and E).
STAT3 is a transcription factor and its activity toward
the reporter gene APRE (35) could be enhanced by
PRMT1 instead of PRMT1(XGX) in the presence of
Figure 4. Continued.
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icantly repressed by TR3 in a dose-dependent manner
(Figure 5F). Sam68 is an RNA-binding protein and
methylated Sam68 would be imported into the nucleus
to exert its function (34). Similar to AdOx, TR3 could
eﬀectively block the nuclear entry of Sam68, resulting in
the cytoplasmic accumulation of Sam68, detected by con-
focal microscopy and western blotting (Figure 5G and H).
Taken together, our data demonstrated that TR3, through
the inhibition of PRMT1 methylation activity, negatively
regulates the functions of PRMT1 targets.
TheroleofTR3agonistinPRMT1methyltransferaseactivity
Very recently, we screened a bank of natural products
from fungi and found an agonist for TR3, called
cytosporone B (Csn-B) (36). We expected that Csn-B
would have similar inhibitory eﬀect as TR3 on PRMT1
methyltransferase activity. Co-IP assays revealed that the
TR3-PRMT1 interaction was enhanced in response to
Csn-B (Figure 6A). Although it upregulated the expres-
sion level of endogenous TR3 but not that of PRMT1,
Csn-B indeed repressed the PRMT1-induced methylation
of H4 R3 in a dose-dependent manner (Figure 6B). Such
inhibitory eﬀect was abolished when a siRNA against TR3
was introduced into cells to inhibit endogenous TR3
expression (Figure 6C), suggesting that the repression of
PRMT1 methyltransferase activity by Csn-B is directly
mediated by TR3. In addition, we also compared the
occurrence between Csn-B-induced TR3 expression and
TR3-inhibited PRMT1 methyltransferase activity at
Figure 5. TR3 attenuated PRMT1-induced methylation of STAT3 and Sam68. (A) TR3 inhibited the methylation activity of PRMT1 on a broad
spectrum of substrates. Myc-PRMT1, with increasing amount of Flag-TR3 or TR3/D2, was transfected into 293T cells. Cell lysates were prepared
and then subjected to western blotting. The methylation of proteins was detected by anti-dimethyl-Arginine asymmetric antibody (ASYM24). AdOx
was used as a positive control. (B, D) TR3 attenuated PRMT1-induced methylation of STAT3. Flag-STAT3, siPRMT1, Myc-TR3, TR3/D2 and
si-TR3 were transfected into 293T cells as indicated, and then immunoprecipitated with anti-Flag antibody. The methylation of STAT3 was
determined with anti-dimethyl-arginine asymmetric antibody (ASYM24). AdOx treatment was set as a control. (C, E) TR3 abolished PRMT1-
induced methylation of Sam68. Myc-Sam68, siPRMT1, Flag-TR3, TR3/D2 and si-TR3 were transfected into 293T cells as indicated. The methyla-
tion of Sam68 was determined. (F) Eﬀect of TR3 on PRMT1-induced transactivation of STAT3. Increasing amount of PRMT1 or its mutant
PRMT1(XGX), together with Flag-STAT3 or Flag-TR3 were transfected into 293T cells. After transfection, cells were treated with IL6 (10ng/ml)
for 30min. The luciferase activity of APRE reporter gene was determined.
 P<0.05 by two-tailed Student’s t-test. (G) Eﬀect of TR3 on localization
of Sam68. Myc-Sam68 with or without GFP-TR3 was transfected into 293T cells. Nuclear and cytoplasmic fractions were prepared and subjected to
western blotting with anti-Myc antibody. Tubulin and Lamin A were used to quantify the amount of protein loaded in the cytoplasm and nucleus.
(H) Confocal analysis of Sam68 subcellular location regulated by TR3 and its deletion mutant. Myc-Sam68, GFP-TR3 and TR3/D2 were transfected
into 293T cells at diﬀerent combinations as indicated. Cells were immunostained by anti-Myc antibody followed by Texas Red-conjugated secondary
antibody to detect Sam68. Stained cells were visualized with the confocal microscope. AdOx was used as a positive control.
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sion reached the peak at 4h after cells were treated with
Csn-B, and it was at the same time-point when the max-
imal inhibition of H4 R3 methylation was achieved
(Figure 6D). This result further supports the conclusion
that it is the agonist-induced TR3 that contributes to the
inhibition of PRMT1 methyltransferase activity.
Finally, we conﬁrmed the negative regulation of TR3 on
PRMT1 methyltransferase activity in diﬀerent tissues of
wildtype (WT) and TR3 KO C57 mice. In WT mice, dif-
ferent methylation levels of H4 R3 were detected in lung,
liver, heart and muscle. In TR3 KO mice, the methylation
levels of H4 R3 were higher in each tissue as compare to
that in WT mice. We further analyzed the eﬀect of TR3
agonist on PRMT1 methyltransferase activity in the xeno-
graft of nude mice. The tumor samples were obtained
from our previous experiment (36). Western blot analysis
showed that Csn-B increased the TR3 expression level in
the xenograft, resulting in the decrease of H4 R3 methyla-
tion (Figure 6F). Conversely, introducing siRNA against
Figure 5. Continued.
Figure 6. The role of TR3 agonist Csn-B in both cells and mice. (A)
Csn-B enhanced TR3 interaction with PRMT1. HepG2 cells were trea-
ted with Csn-B (10mM) for 5h, and then the cell lysates were prepared.
Co-IP assay was performed as described in Figure 1E. (B) Csn-B inhib-
ited PRMT1 methylation on H4 R3 in HepG2 cells. Cells were treated
with increased doses of Csn-B, and then the in vivo methylation of H4
R3 was examined with anti-methyl-H4 R3 antibody. The expression
levels of PRMT1, TR3 and Histone H4 were determined by western
blotting. (C) Inhibition of Csn-B on PRMT1 methylation was abolished
by siRNA against TR3. HepG2 cells were transfected with si-TR3 and
then treated with increased doses of Csn-B. The in vivo methylation of
H4 R3 was examined with anti-methyl-H4 R3 antibody. (D) A correla-
tion between increased TR3 expression level and reduced PRMT1
methylation activity upon Csn-B treatment. HepG2 cells were treated
with Csn-B for the indicated times. The in vivo methylation of H4 R3
was examined with anti-methyl-H4 R3 antibody. (E) Comparison of
methylation activity of H4 R3 between wild-type C57 mice and
TR3
–/– C57 mice. Diﬀerent tissues, including lung, liver, heart and
muscle, were taken from the mice. Protein lysates were prepared, sepa-
rated by SDS-PAGE and probed with anti-methyl-H4 R3, anti-
PRMT1, Histone H4 and anti-Tubulin antibodies, respectively. (F)
Eﬀect of Csn-B on PRMT1 methyltransferase activity in nude mice.
Nude mice were devised into four groups: lane 1, the mice were injected
with gastric cancer BGC-823 cells; lane 2, the mice were injected with
expressing siRNA-TR3 BGC-823 cells; lane 3, the mice were admini-
strated with the dose of 50ng Csn-B/g bodyweight intraperitoneally
every 3 days for 4 weeks; lane 4, the mice expressing si-TR3 were
administrated with Csn-B the same as the lane 3 group. Four weeks
later, the mice were executed and the formed tumors were taken.
Protein lysates were prepared, separated by SDS-PAGE and probed
with anti-methyl-H4 R3, -PRMT1, -TR3, Histone H4 and -Tubulin
antibodies, respectively.
844 Nucleic Acids Research, 2009, Vol. 37, No. 3TR3 reversed the methylation of H4 R3 to even a higher
level than that of the control regardless of the presence of
Csn-B (Figure 6F). These results demonstrated the nega-
tive correlation between TR3 expression and PRMT1
methylation activity in vivo, and revealed the possibility
to use TR3 agonist as a candidate inhibitor of PRMT1.
DISCUSSION
Although arginine methylation represents an emerging
mechanism to regulate protein functions, how PRMT1
regulates its methylation substrates or how its methyl-
transferase activity is regulated by other factors are still
largely unknown. In the current study, we established a
novel feedback regulatory loop between PRMT1 and the
orphan receptor TR3 (Figure 7). Although PRMT1 does
not methylate TR3, it interacts with TR3 and promotes
the DNA binding and transactivation activity of TR3.
On the other hand, by binding to the catalytic region
of PRMT1, TR3 inhibits the methyltransferase activity
of PRMT1.
PRMT1 has been demonstrated as an important argi-
nine-speciﬁc histone methyltransferase. It can methylate
histone H4at Arg-3 in vivo and in vitro (37,31,32), thereby
enhancing transcriptional activation by nuclear receptors
(32,38). PRMT1 is recruited to promoters of speciﬁc genes
through direct interaction with DNA-binding transcrip-
tion factors, such as p53 and YY1 (39,40), or by binding
to other coactivators, such as the p160 coactivator
GRIP1, which associates directly with nuclear receptors
and many other types of DNA-binding transcription
factors (38). Previous studies suggest that the enzymic
activity is required for promoter-associated PRMT1
to stimulate transcriptional activation (31,41). However,
our ﬁnding that the PRMT1(XGX) mutant deﬁcient
of methyltransferase activity could also promote the
DNA binding of TR3 and contributed to transcriptional
activation suggests that the methyltransferase activity of
PRMT1 is not necessary for its coactivator function, at
least in the case of TR3. Moreover, we found that PRMT1
truncation mutants that had lost the ability to methylate
H4 R3 still retained the ability to enhance TR3 transacti-
vational activity, further suggesting that activation of
TR3 transactivation is not associated with PRMT1
methyltransferase activity. Therefore, it is likely that the
methyltransferase activity of PRMT1 and its ability to
bind nuclear receptors both contribute to its coactivator
function.
SRCs have been shown to act as coactivators to facil-
itate nuclear receptor DNA binding (42). We observed a
synergistic eﬀect of SRC-2 and PRMT1 on TR3 transac-
tivation. Both coactivators interacted with the LBD of
TR3 and either one could enhance TR3 binding to the
cyclin D2 promoter that contains a TR3 response element.
Although we cannot decide which coactivator played
a main role in TR3 transactivation, according to the fact
that SRC-2 could not upregulate TR3 expression
levels (data not shown), we propose that PRMT1 may
ﬁrst interact with TR3 to induce its accumulation, thereby
increasing its DNA-binding capacity. Then, SRC-2, via an
unknown mechanism that may involve PRMT1, bound to
TR3 to exert synergistic eﬀect, and ﬁnally co-initiate the
transcription of TR3 target genes. Therefore, PRMT1
may be a device for speciﬁc activation of NurRE-contain-
ing promoters.
So far, litter is known about how the methyltransferase
activity of PRMT1 is regulated. The members of PRMT
family have been found to interact with proteins that are
often not methyl-accepting substrates but can modulate
the methyltransferase activity of PRMTs through distinct
mechanisms. For example, tumor suppressor DAL-1/4
functions as an inhibitor of PRMT3 activity through
interaction (14). By contrast, it regulates PRMT5 activity
by either repressing or enhancing protein methylation
(15). PRMT1 has been identiﬁed as an interacting protein
of the immediate early gene product BTG1 (B-cell trans-
location gene 1), which also modulates PRMT1 activity
toward selected substrates (4,43). In addition, hCAF1, a
partner of BTG1 and BTG2, was also found to regulate
PRMT1 activity in a substrate-dependent manner (44).
Our current study revealed that, TR3, another immediate
early gene product (45), also plays a regulatory function
on PRMT1 activity.
Figure 7. A working model to illustrate the feedback regulatory loop
between PRMT1 methyltransferase activity and TR3 protein level.
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ity is through protein–protein interaction. The critical step
might be the binding of TR3 to the catalytic domain of
PRMT1, which causes the loss of its methyltransferase
activity. The binding region of TR3 on PRMT1 is diﬀer-
ent from that of Histone H4, Sam68 and STAT3, the
latter bound to the substrate-binding domain of
PRMT1. This may explain why PRMT1 cannot methylate
TR3, although TR3 contains a glycine- and arginine-rich
motif ‘GRRGR’ in its DBD. On the other hand, although
only full-length PRMT1 eﬀectively methylates H4 R3, our
results indicated that the N-terminus of PRMT1 plays an
important role in regulation of TR3 function, including
expression levels and transactivation activity of TR3.
In fact, N-terminus are the major regions where at least
11 human PRMTs diﬀer from each other (2), and has been
reported to be important for recognizing its target sub-
strates (46). It seems that the functions of this N-terminus
may depend on the nature of the protein substrate
involved.
Repression of PRMT1 activity by its interaction partner
would indirectly aﬀect the functions of its substrates. The
Sam68 RNA-binding protein is methylated in vivo by
PRMT1, and inhibition of Sam68 methylation by deletion
of the methylation sites or use of methylation inhibitor
causes accumulation of Sam68 in the cytoplasm and pre-
vents Sam68-mediated export of HIV RNAs (34). We also
observed reduced Sam68 nuclear localization when TR3
was expressed. Similarly, the transcriptional activity
of STAT3 induced by PRMT1 methylation was also
inhibited by TR3. These two events could all be attributed
to the repression of PRMT1 methylation activity by TR3.
Therefore, PRMT1 may provide a platform for TR3 to
regulate other protein functions.
One particular interesting ﬁnding from our study is that
an agonist for TR3 can inhibit methyltransferase activity
of PRMT1 through activating TR3. Data from cell cul-
tures and mice both indicated the existence of a negative
correlation between TR3 expression level and PRMT1
methyltransferase activity. This ﬁnding is signiﬁcant for
the therapeutic application of TR3 agonist, because
many diseases have been shown to be correlated with
aberrant arginine methylation. For example, asymmetric
dimethylarginine (ADMA) is synthesized when arginine
residues in proteins are methylated by the action of
PRMTs (47,2). ADMA inhibits nitric oxide syntheses
(NOS) (48), and therefore has the potential to produce
detrimental biological eﬀects, particularly in the cardio-
vascular system. Recently, several studies have suggested
that the plasma concentrations of ADMA provide a
marker of risk for endothelial dysfunction and cardiovas-
cular disease (48–51). Therefore, it is of interesting to
further investigate the role of TR3 agonist through regu-
lation of methyltransferase activity, which may lead to
new therapeutic applications.
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